Header image

Joel Schlessinger MD donates to the Avon Walk for Breast Cancer

Posted by Joel Schlessinger in Community

Joel Schlessinger MD donates to the Avon Walk for Breast Cancer
With his recent donation, Joel Schlessinger MD shows his support for breast cancer awareness. His donation to the 2013 Avon Walk for Breast Cancer will help patients and their families gain access to the care they need and bring the foundation closer to finding a cure for breast cancer.

Started by the Avon Foundation for Women in 2003, the Avon Walk for Breast Cancer is a national series of weekend fundraising events. The event, held in 8 cities across the country every year, includes a 39-mile walk to raise awareness for breast cancer research. Since its inception, participants have walked 5,261,811 miles – enough to circle the globe more than 201 times.

The donation made by Joel Schlessinger MD supports the Avon Foundation for Women.

The Avon Foundation for Women is dedicated to improving the lives of women and their families. Aside from working to impact breast cancer research and easy access to care, this foundation is dedicated to domestic violence education, prevention and victim services. The annual breast cancer walk is just one way the Avon Foundation for Women makes a difference.

The Avon Foundation for Women’s mission is important to Joel Schlessinger MD.

As a husband and a father, Joel Schlessinger MD supports the foundation’s mission to assist women and their families. He and his family have supported and participated in different fundraising races for several years. Joel Schlessinger MD’s e-commerce site, LovelySkin.com, also sells products with the pink ribbon during Breast Cancer Awareness Month, where cosmeceutical brands donate a percentage of their profits to fund further research.

For more information about the Avon Walk for Breast Cancer or to donate to the cause, visit the foundation’s website.

Have you or someone you love participated in the Avon Walk for Breast Cancer? Share your story with us in the comments.

You can follow any responses to this entry through the RSS 2.0 You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply

Your email address will not be published. Required fields are marked *